(RTTNews) - Merck (MRK) and Imago BioSciences, Inc. (IMGO) have entered into a definitive agreement under which Merck, through a subsidiary, will acquire Imago for $36.00 per share in cash for an ...
Merck is shoring up its drug pipeline with the $1.35 billion buyout of Imago BioSciences, a biotech developing blood and bone marrow disorder therapies that could offer advantages over currently ...
Imago is developing new medicines for the treatment of myeloproliferative neoplasms and other bone marrow diseases. Merck has agreed to buy biopharmaceutical company Imago BioSciences Inc. for about ...
Merck will acquire Imago BioSciences, a pharmaceutical company that focuses on treatments for bone marrow diseases, for $1.35 billion, the drugmaker said Nov. 21. Imago’s main prize is bomedemstat, a ...
Merck announced Monday morning that it is acquiring Imago BioSciences for $1.35 billion. Imago is a clinical stage biopharmaceutical company developing treatments for myeloproliferative neoplasms and ...
REDWOOD CITY, Calif., Dec. 20, 2022 (GLOBE NEWSWIRE) -- Imago BioSciences, Inc (IMGO). (“Imago” or the “Company”) (Nasdaq: IMGO), a clinical-stage biopharmaceutical company discovering and developing ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback